How I treat common variable immune deficiency

被引:219
作者
Cunningham-Rundles, Charlotte [1 ]
机构
[1] Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
MEMORY B-CELLS; PRIMARY IMMUNODEFICIENCY DISEASES; OF-THE-LITERATURE; NODULAR REGENERATIVE HYPERPLASIA; INTERNET-BASED PATIENT; ANTIBODY-DEFICIENCY; INTRAVENOUS IMMUNOGLOBULIN; GRANULOMATOUS-DISEASE; PRIMARY HYPOGAMMAGLOBULINEMIA; IGA DEFICIENCY;
D O I
10.1182/blood-2010-01-254417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Common variable immunodeficiency is a rare immune deficiency, characterized by low levels of serum immunoglobulin G, A, and/or M with loss of antibody production. The diagnosis is most commonly made in adults between the ages of 20 and 40 years, but both children and older adults can be found to have this immune defect. The range of clinical manifestations is broad, including acute and chronic infections, inflammatory and autoimmune disease, and an increased incidence of cancer and lymphoma. For all these reasons, the disease phenotype is both heterogeneous and complex. Contributing to the complexity is that patient cohorts are generally small, criteria used for diagnosis vary, and the doses of replacement immune globulin differ. In addition, routines for monitoring patients over the years and protocols for the use of other biologic agents for complications have not been clarified or standardized. In the past few years, data from large patient registries have revealed that both selected laboratory markers and clinical phenotyping may aid in dissecting groups of subjects into biologically relevant categories. This review presents my approach to the diagnosis and treatment of patients with common variable immunodeficiency, with suggestions for the use of laboratory biomarkers and means of monitoring patients. (Blood. 2010; 116(1): 7-15)
引用
收藏
页码:7 / 15
页数:9
相关论文
共 101 条
[1]   Gastrointestinal Manifestations in Primary Immune Disorders [J].
Agarwal, Shradha ;
Mayer, Lloyd .
INFLAMMATORY BOWEL DISEASES, 2010, 16 (04) :703-711
[2]   Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes [J].
Agarwal, Shradha ;
Mayer, Lloyd .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (04) :658-664
[3]   Absence of memory B cells in patients with common variable immunodeficiency [J].
Agematsu, K ;
Futatani, T ;
Hokibara, S ;
Kobayashi, N ;
Takamoto, M ;
Tsukada, S ;
Suzuki, H ;
Koyasu, S ;
Miyawaki, T ;
Sugane, K ;
Komiyama, A ;
Ochs, HD .
CLINICAL IMMUNOLOGY, 2002, 103 (01) :34-42
[4]   Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency [J].
Alachkar, Hana ;
Taubenheim, Nadine ;
Haeney, Mansel R. ;
Durandy, Anne ;
Arkwright, Peter D. .
CLINICAL IMMUNOLOGY, 2006, 120 (03) :310-318
[5]   Granulomatous disease in common variable immunodeficiency [J].
Ardeniz, Oemuer ;
Cunningham-Rundles, Charlotte .
CLINICAL IMMUNOLOGY, 2009, 133 (02) :198-207
[6]   Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and a review of the literature of vitamin E deficiency [J].
Aslam, A ;
Misbah, SA ;
Talbot, K ;
Chapel, H .
CLINICAL IMMUNOLOGY, 2004, 112 (01) :24-29
[7]   Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency-possible immunologic and clinical consequences [J].
Aukrust, P ;
Lien, E ;
Kristoffersen, AK ;
Muller, F ;
Haug, CJ ;
Espevik, T ;
Froland, SS .
BLOOD, 1996, 87 (02) :674-681
[8]   Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%) [J].
Ballow, M ;
Berger, M ;
Bonilla, FA ;
Buckley, RH ;
Cunningham-Rundles, CH ;
Fireman, P ;
Kaliner, M ;
Ochs, HD ;
Skoda-Smith, S ;
Sweetser, MT ;
Taki, H ;
Lathia, C .
VOX SANGUINIS, 2003, 84 (03) :202-210
[9]   Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency [J].
Bates, CA ;
Ellison, MC ;
Lynch, DA ;
Cool, CD ;
Brown, KK ;
Routes, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) :415-421
[10]   A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma® [J].
Berger, Melvin .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (06) :628-633